Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine says go, doctor says no: an ecological momentary assessment analysis examining clinicians' perceptions of, and their antibiotic prescribing behaviour when using rapid molecular diagnostic tests in intensive care.

Antimicrobial resistance and infection control·2026
Same author

Cefalexin use in UK acute pyelonephritis practice: unaddressed challenges in dosing, breakpoints and clinical evidence.

The Journal of antimicrobial chemotherapy·2026
Same author

Assessing antimicrobial susceptibility testing guideline adherence by laboratories providing bacteriology services in Ghana: a pilot study.

The Journal of antimicrobial chemotherapy·2026
Same author

Importance of reviewing the package insert from gradient strip manufacturers.

The Journal of antimicrobial chemotherapy·2025
Same author

Rifampicin as monotherapy for infections caused by Staphylococcus aureus: considerations for not applying 'breakpoints in brackets'.

The Journal of antimicrobial chemotherapy·2025
Same author

The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations.

The Journal of antimicrobial chemotherapy·2025

Related Experiment Video

Updated: Jun 29, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Future directions with daptomycin.

David M Livermore1

  • 1Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency Centre for Infections, London, UK. david.livermore@hpa.org.uk

The Journal of Antimicrobial Chemotherapy
|October 10, 2008
PubMed
Summary

Daptomycin is a novel antibiotic for serious infections, but resistance is emerging in MRSA cases. Further research is needed to optimize its use and compare it against other new agents.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Trials

Background:

  • Daptomycin represents a new class of natural-product antibiotics.
  • It is approved for skin and soft tissue infections, staphylococcal bacteraemia, and endocarditis.
  • Ongoing trials explore its efficacy in enterococcal endocarditis and neutropenic fevers.

Purpose of the Study:

  • To review the current status and future directions for daptomycin therapy.
  • To identify areas requiring further clinical investigation, such as bone and joint infections.
  • To address the emergence of daptomycin resistance in Staphylococcus aureus infections.

Main Methods:

  • Review of existing clinical data and published literature on daptomycin.
  • Analysis of emerging resistance patterns, particularly in methicillin-resistant Staphylococcus aureus (MRSA).

More Related Videos

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Related Experiment Videos

Last Updated: Jun 29, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

  • Evaluation of the competitive landscape with other novel anti-Gram-positive agents.

    • Main Results:

    • Daptomycin shows potential in complex infections but faces challenges with emerging resistance.
    • High bacterial load settings may increase the risk of resistance development.
    • Optimal dosing and combination therapies require further investigation.

    Conclusions:

    • Further trials are essential to define daptomycin's role in specific infections like bone and joint infections.
    • Strategies to mitigate resistance, such as higher doses or combination therapy, need evaluation.
    • Comparative studies are necessary to establish daptomycin's advantages over existing and emerging antibiotics.